FDA: Retisert Can Cause Cataracts

Jim Marino — Mon, 10 Nov 2008 07:55:09 +0000

The U.S. food and Drug Administration has approved safety labeling revisions for Bausch & Lomb, Inc.’s Retisert (a fluocinolone acetonide intravitreal implant). The new labeling includes warnings based on the now available 3-year clinical reports. Use of the product can cause cataracts which require surgical removal in all phakic eyes within an average 3-year period. About 77% of patients will need drugs to lower intraocular pressure (IOP) within this period, and around 37% of patients may require filtering procedures for controlling elevated IOP.

Research shows lower CSF pressure in glaucoma patients

Jim Marino — Tue, 13 May 2008 17:17:52 +0000

Researchers have found that cerebrospinal fluid (CSF) pressure was a third lower in patients with primary open-angle glaucoma than in those who did not have the condition. The group of researchers led by John Berdahl also found in a retrospective case-control study that intraocular pressure (IOP) was similar between patients with glaucoma and those with other vision defects. The research published in the May issue of Ophthalmology suggests that the pressure difference between the intraocular space and the CSF space, the so-called translaminar pressure difference, may play a role in the pathogenesis of glaucoma.

Optometry Product Guide » intraocular pressure

FDA: Retisert Can Cause Cataracts

Research shows lower CSF pressure in glaucoma patients